Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728196 | 0.86 | TAAR1 (0.45) | KMT2A | |
| SCHEMBL4891509 | 0.82 | L3MBTL1 (0.40) | MAPK1L3MBTL1TDP1KMT2ACYP2D6 | |
| SCHEMBL4731615 | 0.81 | PNMT (0.41) | TSHR | |
| SCHEMBL4729192 | 0.80 | OPRK1 (0.40) | MAPK1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL4728453 | 0.73 | SLC6A2 (0.35) | CYP2D6KCNH2CYP3A4CYP2C9 | |
| SCHEMBL4895988 | 0.70 | OPRK1 (0.38) | TSHRKMT2ACYP3A4 | |
| SCHEMBL4730804 | 0.70 | SMN1; SMN2 (0.37) | MAPK1L3MBTL1TSHRKMT2ACYP3A4 | |
| SCHEMBL4894642 | 0.69 | HEXA (0.43) | MAPK1L3MBTL1KMT2APOLB | |
| SCHEMBL6401312 | 0.69 | CA1 (0.40) | L3MBTL1POLBCYP3A4 | |
| SCHEMBL15568242 | 0.68 | KMT2A (0.53) | MAPK1L3MBTL1TSHRTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | MAPK1 115/4885L3MBTL1 1483/4885TSHR 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.